Following menopause, up to 49% of women will experience genitourinary symptoms such as vaginal itching, dryness, dyspareunia and incontinence as a result of oestrogen deficiency. Treatments such as vaginal lubricants and moisturisers only temporarily relieve symptoms, while local oestrogen treatments are often unacceptable or unsafe for many women. Recently, a novel laser treatment has been proposed as a non-invasive, long-term solution to vulvo-vaginal and urinary symptoms. While preliminary histological results have been promising, its therapeutic, clinical effect has yet to be determined. However, despite the scarcity of evidence for its safety and long-term benefit, laser treatments are widely marketed for a range of genitourinary symptoms, with high uptake by both clinicians and women alike. This review aims to examine the evidence for laser treatments to the vulvo-vagina and to evaluate its safety and efficacy. Our results include 17 studies investigating the effect of laser therapy for vulvo-vaginal symptoms, seven for its effects on urinary incontinence and four for histology. These are limited to non-randomised, observational data with small sample sizes between 15 to 175 women and follow-up duration from none to two years. As such, strong evidence for laser efficacy and safety is limited and warrants more robust, placebo-controlled, randomised trials before widespread implementation.
INTRODUCTION
Vulvo-vaginal symptoms (VVS) for the postmenopausal woman are a common cause of presentation to health care professionals, with up to 49% of postmenopausal women affected and causing a major impact on quality of life. 1 Specific symptoms such as dyspareunia may have a detrimental impact on relationships and contribute to reduced self-esteem and emotional wellbeing. 2 The local vulvo-vaginal atrophic changes lead to epithelial thinning, loss of vaginal rugae and decreased vaginal vascularisation. 3, 4 In turn, this results in loss of elasticity and lubrication as well as shortening and narrowing of the vaginal canal, 3 with vulvo-vaginal atrophy (VVA) (more recently referred to as genitourinary syndrome of menopause/GSM), 5 manifesting as vaginal dryness, itching, irritation, abnormal discharge and dyspareunia, with associated urinary symptoms of frequency, urgency and incontinence. 6 Changes to the vaginal microbiome may also lead to an increased risk and recurrence of genitourinary infections.
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Treatment of vulvo-vaginal symptoms may be hormonal or non-hormonal. Non-hormonal lubricants and moisturisers only provide short-term symptom relief and require regular application, but are safe for long-term use. 8 Local, low-dose oestrogen is the mainstay of hormonal treatment; 3 however, these may be unacceptable or contra-indicated in women with increased risk of thromboembolic disease and those with oestrogendependent breast cancer. 8 Sixty-three percent of women with breast cancer surveyed experienced genitourinary symptoms associated with VVA, 9 but systemic absorption of topical vaginal treatments may increase circulating oestrogen levels, although the level of absorption is considered to be minimal. 8, 10, 11 Vulvo-vaginal laser treatment has been proposed as an alternative treatment for VVA, where microscopic areas of thermal necrosis to the vaginal skin induce a healing cascade to change a number of physical skin components. 12 Micro-ablative, fractional CO 2 and erbium-doped yttrium aluminium garnet creased glycogen storage and fibroblast activity. [13] [14] [15] However, evidence for symptom control and improvements to quality of life, duration of effect and safety is less concrete. This systematic review aims to assess the evidence for the clinical efficacy, safety and duration of effect of current marketed laser therapies to the vulvo-vagina, to ensure such proposed treatments are evidence-based.
METHODS
We performed a systematic review using a protocol registered with PROSPERO (#CRD42017064916 
Main outcomes Adverse events Comments
• Significant decrease in median VAS scores from baseline to last treatment EXCEPT in vaginal laxity (P < 0.001 for all, P < 0.008 for dysuria)
None reported
• Significant, progressive improvement in dyspareunia and pain scores at each treatment and follow-up (P <
• Significant reduction in VAS scores across all
domains at six months in both groups (P < 0.05) with improvements maintained and better in laser than oestrogen by 12 and 18 months • Significant improvement in MV and pH in both groups at three months (P < 0.001) but laser maintained a significant and better improvement at 12 months (P < 0.001) while oestrogen group pH returned to baseline Figure 1 reports the results of our systematic review. All studies were published between 2012 and 2017, with no published RCTs to date, although three were identified as being underway through trial registries. Of the included studies, four [13] [14] [15] [16] 25 and the remaining, prospective studies. Followups ranged from none to two years post-treatment with a 45% to 100% completion rate. Table 1 summarises the characteristics of studies that measured laser therapy effects on VVA and Table 2 summarises those related to urinary incontinence. 
RESULTS

DISCUSSION
40,41
The traditional evidence pyramid should progress efficiently from initial case reports and series that determine that an innovative treatment with biological plausibility may be performed and may preliminary data demonstrating significant symptomatic improvement. 44 Subsequently, two randomised, placebo-controlled trials showed no difference between the placebo and the intervention groups. 45, 46 Even for treatments proven effective in the short term, post-market monitoring may reveal long-term adverse events, as was the case with many vaginal mesh kits that has led to multiple cancellations of the devices by the Therapeutic Goods
Administration and a senate enquiry into a variety of procedures in the pelvic floor. This is not to say that all new treatments are ineffective and should not be used. However, safe, rational and appropriate use by critically appraising the literature for sound evidence before using a treatment is imperative to ensure patient safety and benefit.
While the availability of levels of evidence may be in flux, 47 the need for that evidence is not. Prospective observational studies are the predominant evidence currently available for laser treatments of VVS and these report an effect that is an excellent springboard to the next level of evidence, the placebo-controlled study, and since none are currently available, the essential data for clinicians, patients and industry alike remain uncertain. 48 There are currently four studies 26, 27, 30, 37 that use a control group for comparison, but none of these are randomised and none have a placebo control. While placebo-controlled trials are registered, large-scale treatment using vulvo-vaginal laser is already being marketed and provided as a solution when the trials are still incomplete.
Studies without blinded, control groups are highly susceptible to the placebo effect that is documented to cause positive physiological and/or physical changes without actual treatment due to participant expectation of a response. 49 Responses may even be seen when participants are aware of taking a placebo 50 and the effect is particularly prominent in subjective, patient-reported outcomes 51 -the predominant outcome measures in studies of laser treatment so far.
The studies to date do examine histology in a small series and this provides some objective data; however, it is longitudinal, symptomatic improvement that is the final arbiter of success for this problem and with less than 50 women having follow-up to two years, 32 the success of the treatment cannot be considered more than hypothesis. Furthermore, selection bias and the small numbers preclude determination of safety and substantive efficacy, which must be established before being offered to women The potential for a non-invasive way to treat stress urinary incontinence is very attractive, particularly in the current setting of litigation and class actions that involve midurethral slings. 55 This is in the face of good evidence that the procedures are highly effective in well-conducted large-scale randomised trials. 56 However, to date, the evidence for laser treatment for stress urinary incontinence is tenuous at best with a small number of women treated and only followed up in the short term (up to six months and one study to one year). 36 While statistically significant improvements in subjective scores were noted, the improvements often diminished by six months. 37, 39 Since urinary incontinence is a chronic issue, the determination that it is indeed better than placebo and the duration of its effect, the need to repeat treatments, their efficacy and costs compared with current standard treatments must be considered.
All studies included for urinary incontinence investigated changes in stress urinary incontinence with one 36 studying mixed incontinence and reporting a reduced effect in this setting (77% vs 34% improvement in stress vs mixed incontinence, respectively, P < 0.001) and caution must be given in areas where the data are limited or extrapolated.
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Of the 26 studies involving vaginal treatment (excluding one 14 ex vivo study), 12 15, 17, 20, 21, 24, 26, 29, 31, [33] [34] [35] reported no adverse events.
Reported events included procedure pain with probe insertion and movement, introitus irritation post-treatment, a burning sensation and minor bleeding. All adverse events noted were transient and spontaneously resolved within a few hours or days of treatment.
No long-term adverse events were recorded and it is perhaps this simple approach in an ambulatory setting with many applications that make the treatment attractive for both clinician and patient alike. Certainly media reports suggest benefit 57 and this often advertorial rather than editorial approach must be tempered by science and the clinical community must impose that science.
CONCLUSION
Urogenital symptoms associated with VVA are a significant burden on women and the development of non-invasive, simple treatment methods such as laser therapy, is welcome. However, 
